Regeneron board member and executive sell $1 million in stock after Trump touts treatment
“These are pre-established at a time when the executive/director is not aware of any material, nonpublic information about Regeneron,” a spokesperson said.
Related Articles
Does STEMI Need a Rebrand to ‘Occlusion MI’?
A review paper prompted a discussion among cardiologists Bob Harrington, Manesh Patel, and Michael Gibson on whether the ST-segment elevation myocardial infarction paradigm needs an…
Publishers are selling papers to train AIs — and making millions of dollars
Nature – Generative-AI models require massive amounts of data — scholarly publishers are licensing their content to train them.
Does STEMI Need a Rebrand to ‘Occlusion MI’?
A review paper prompted a discussion among cardiologists Bob Harrington, Manesh Patel, and Michael Gibson on whether the ST-segment elevation myocardial infarction paradigm needs an…
Publishers are selling papers to train AIs — and making millions of dollars
Nature – Generative-AI models require massive amounts of data — scholarly publishers are licensing their content to train them.
Dr. Oz Will Have a Fascinating Conflict of Interest Running Medicare: Ozempic
Trump’s top pick to lead Medicare, Dr. Mehmet Oz, has a glaring conflict of interest: that he was sponsored by the company that makes Ozempic.
Novartis cannot block generic of best-selling heart drug, US appeals court says
Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals’ proposed generic of Novartis’ blockbuster heart drug Entresto.
There’s an effective treatment for menopause symptoms. Why do so few women use it?
Misconceptions about the risks of hormone therapy have stuck around even in the wake of new research.
There’s an effective treatment for menopause symptoms. Why do so few women use it?
Misconceptions about the risks of hormone therapy have stuck around even in the wake of new research.
Cervical cancer deaths are plummeting among young U.S. women
A new study shows a steep drop in cervical cancer deaths among the first cohort of women who were eligible for the HPV vaccine.
Cervical cancer deaths are plummeting among young U.S. women
A new study shows a steep drop in cervical cancer deaths among the first cohort of women who were eligible for the HPV vaccine.